111 related articles for article (PubMed ID: 34806545)
21. Correlations between CD4
Ma K; Li X; Lv J; Liu Z; Zhang L; Cong H; Wang H; Shen F; Yue L
Asia Pac J Clin Oncol; 2021 Apr; 17(2):e63-e69. PubMed ID: 31957250
[TBL] [Abstract][Full Text] [Related]
22. HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis.
Yan Y; Lu L; Liu C; Li W; Liu T; Fu W
Clin Res Hepatol Gastroenterol; 2015 Feb; 39(1):121-6. PubMed ID: 25176587
[TBL] [Abstract][Full Text] [Related]
23. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.
Jeung J; Patel R; Vila L; Wakefield D; Liu C
Arch Pathol Lab Med; 2012 Jun; 136(6):610-7. PubMed ID: 22646266
[TBL] [Abstract][Full Text] [Related]
24. Significance of effector protease receptor-1 expression and its relationship with proliferation and apoptotic index in patients with primary advanced gastric adenocarcinoma.
Yao XQ; Liu FK; Li JS; Qi XP; Wu B; Yin HL; Ma HH; Shi QL; Zhou XJ
World J Gastroenterol; 2004 May; 10(9):1262-7. PubMed ID: 15112339
[TBL] [Abstract][Full Text] [Related]
25. Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study.
Wei Z; Huang L; Zhang X; Xu A
BMC Gastroenterol; 2020 Oct; 20(1):343. PubMed ID: 33059614
[TBL] [Abstract][Full Text] [Related]
26. [Association of HER-2/neu expression with prognosis of gastric cancer].
Chen B; Luo RC; Cui F; Qian XY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):344-7. PubMed ID: 16546744
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma.
Kim H; Seo S; Kim K; Park YH; An M; Baik H; Choi C; Oh S
World J Surg Oncol; 2019 Jul; 17(1):122. PubMed ID: 31296222
[TBL] [Abstract][Full Text] [Related]
28. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
[TBL] [Abstract][Full Text] [Related]
29. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays.
Kim KC; Koh YW; Chang HM; Kim TH; Yook JH; Kim BS; Jang SJ; Park YS
Ann Surg Oncol; 2011 Oct; 18(10):2833-40. PubMed ID: 21468783
[TBL] [Abstract][Full Text] [Related]
31. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of HER2/neu expression in gastric cancer.
Ananiev J; Gulubova M; Manolova I; Tchernev G
Wien Klin Wochenschr; 2011 Jul; 123(13-14):450-4. PubMed ID: 21739203
[TBL] [Abstract][Full Text] [Related]
33. Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.
Lv J; Yao YS; Zhou F; Zhuang LK; Yao RY; Liang J; Qiu WS; Yue L
Med Oncol; 2014 Nov; 31(11):280. PubMed ID: 25297519
[TBL] [Abstract][Full Text] [Related]
34. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.
Warneke VS; Behrens HM; Böger C; Becker T; Lordick F; Ebert MP; Röcken C
Ann Oncol; 2013 Mar; 24(3):725-33. PubMed ID: 23139264
[TBL] [Abstract][Full Text] [Related]
35. FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients.
Kim MH; Koo JS; Lee S
Oncology; 2013; 85(2):128-36. PubMed ID: 23948758
[TBL] [Abstract][Full Text] [Related]
36. HER2, NF-
Smolińska M; Grzanka D; Antosik P; Kasperska A; Neska-Długosz I; Jóźwicki J; Klimaszewska-Wiśniewska A
Dis Markers; 2019; 2019():6315936. PubMed ID: 31737131
[TBL] [Abstract][Full Text] [Related]
37. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
38. HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach.
Ieni A; Barresi V; Rigoli L; Caruso RA; Tuccari G
Dis Markers; 2015; 2015():234851. PubMed ID: 26494937
[TBL] [Abstract][Full Text] [Related]
39. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
Song Y; Huang J; Wang JW
Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
[TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
